RxDoctor Payments Data

Heng Chao Wei, MD

Internal Medicine · Ossining, NYNPI 1871981332

Payments from drug & device makers

$4,529in general payments, 2019–2025

Across 193 payments — averaging $23.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Novo Nordisk$899
  • Amarin Pharma, Inc.$607
  • Johnson & Johnson$294
  • Heartflow, Inc.$192
  • Bayer$176
  • plus $1K from 14 others

What the payments were for

  • Food & beverage$4,515100%
  • Education$140%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,529 in reported general payments places this provider in the 85th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$193,512
Medicare patients
357
Services billed
2,339

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide80$137,616
JardianceEmpagliflozin73$88,526
EliquisApixaban71$70,707
RybelsusSemaglutide33$54,190
TrulicityDulaglutide19$35,710
Synjardy XrEmpagliflozin/Metformin Hcl33$30,371
MounjaroTirzepatide16$18,013
VascepaIcosapent Ethyl30$17,230
InvokanaCanagliflozin28$15,655
Atorvastatin Calcium724$8,270
Icosapent Ethyl19$5,715
NamzaricMemantine Hcl/Donepezil Hcl13$5,190
Fluticasone-SalmeterolFluticasone Propion/Salmeterol25$4,064
Rosuvastatin Calcium169$4,047
Valsartan115$3,732

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$899$191,806113 claims
Boehringer IngelheimJardiance, Synjardy Xr$124$118,897106 claims
PfizerEliquis$63$70,70771 claims
Lilly USA, LLCTrulicity, Mounjaro$172$53,72335 claims
Johnson & JohnsonInvokana$294$15,65528 claims
AbbVieNamzaric, Synthroid$1,277$6,83547 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in Ossining

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →